Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP014: Impact of genetic variation on gene and protein expression in Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

A. Hart*, K. Hayden, E. Wadman, S. Bhagat, D. Jacobstein, C. Brodmerkel, J. Friedman, K. Li

Janssen Research & Development, LLC, Spring House, USA

DOP015: Dysregulation of cell-type-specific long ncRNA in the ileum of treatment naïve early onset Crohn diseaseECCO '18 Vienna
Year: 2018
Authors:

Y. Haberman1,2*, M. BenShoshan1, A. Di Segni1, P.J. Dexheimer3, T. Braun1, B. Weiss1, C. Avivi1, I. Barshack1, Y. Anikster1, B. Aronow3, J.S. Hyams4, S. Kugathasan5, L.A. Denson3, The Crohn's & Colitis Foundation (CCF)-sponsored RISK study

1Sheba Medical Center, Tel Hashomer, Israel, 2CCHMC, Cincinnati, USA, 3Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA, 4Connecticut Children’s Medical Center, Hartford, USA, 5Emory University, Atlanta, USA

DOP016: Metagenomic analysis of intestinal mucosa revealed an IBD-specific shift in the eukaryotic gut virome composition at early stages of gut inflammationECCO '18 Vienna
Year: 2018
Authors:

F. Ungaro1*, L. Massimino2, S. D'Alessio1, S. Danese1

1Humanitas University, Biomedical Science, Milan, Italy, 2San Raffaele Scientific Institute, Division of Neuroscience, Milan, Italy

DOP017: Increased intestinal aryl hydrocarbon receptor expression and pathway sensitivity in Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

P. Harrow1,2*, N. McCarthy1, A. Stagg1, J. Lindsay1,2

1Blizard Institute, Immunobiology, London, UK, 2Royal London Hospital, Gastroenterology, London, UK

DOP018: Baseline ILC1 distribution in blood predicts response to ustekinumab in patients with refractory Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

B. Creyns1*, B. Verstockt2,3, J. Cremer1, M. Ferrante2,3, S. Vermeire2,3, C. Jan1, G. Van Assche2,3, C. Breynaert1

1KULeuven, Lab of Clinical Immunology, Leuven, Belgium, 2University Hospital Gasthuisberg, Department of Gastroenterology, Leuven, Belgium, 3KU Leuven, TARGID - Department of Chronic Diseases, Metabolism and Aging, Leuven, Belgium

DOP019: Immunomodulators reduce the risk of surgery and hospitalisation in Crohn’s disease in a prospective European population-based inception cohort: the Epi-IBD cohortECCO '18 Vienna
Year: 2018
Authors:

J. Burisch1*, V. Andersen2,3, S. Čuković-Čavka4, P.L. Lakatos5, R. D'Inca6, F. Magro7,8,9, N. Arebi10, L. Kievit11, I. Kaimakliotis12, D. Valpiani13, K.H. Katsanos14, Z. Vegh5, J.F. Dahlerup15, M. Fumery16, N. Pedersen17, J. Halfvarson18, E. Belousova19, K.R. Nielsen20, S. Turcan21, P. Ellul22, L. Kupcinskas23, P. Oksanen24, D. Duricova25, M. Giannotta26, A. Goldis27, V. Hernandez28, R. Salupere29, S. Odes30, E. Langholz31, P. Munkholm1, Epi-IBD study group

1North Zealand University Hospital, Department of Gastroenterology, Frederikssund, Denmark, 2Viborg Regional Hospital, Medical Department, Viborg, Denmark, 3Hospital of Southern Jutland, Medical Department, Aabenraa, Denmark, 4University Hospital Center Zagreb, University of Zagreb School of Medicine, Division of Gastroenterology and Hepatology, Zagreb, Croatia, 5Semmelweis University, 1st Department of Medicine, Budapest, Hungary, 6Azienda Ospedaliera di Padova, Department of Surgery, Oncology and Gastroenterology, Padova, Italy, 7University of Porto, Institute for molecular and cell biology, Porto, Portugal, 8Hospital de São João, Department of Gastroenterology, Porto, Portugal, 9Oporto Medical School, Institute of Pharmacology and Therapeutics, Porto, Portugal, 10St Mark's Hospital, Gastroenterology, London, UK, 11Herning Central Hospital, Department of medicine, Herning, Denmark, 12Nicosia Private practice, Nicosia Private practice, Nicosia, Cyprus, 13Department of Gastroenterology and Digestive Endoscopy, Morgagni Hospital, Forli, Italy, 14University Hospital, Ioannina, 1st Division of Internal Medicine and Hepato-Gastroenterology Unit, Ioannina, Greece, 15Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark, 16Amiens University and Hospital, Epimad Registry, Gastroenterology Unit, Amiens, France, 17Slagelse Hospital, Department of Gastroenterology, Slagelse, Denmark, 18Faculty of Medicine and Health, Örebro University, Department of Gastronterology, Örebro, Sweden, 19Moscow Regional Research Clinical Institute, Department of Gastroenterology, Moscow, Russian Federation, 20The National Hospital of the Faroe Islands, Medical department, Tórshavn, Faroe Islands, 21State University of Medicine and Pharmacy of the Republic of Moldova, Department of Gastroenterology, Chisinau, Moldova, Republic of, 22Mater Dei Hospital, Division of Gastroenterology, L-Imsida, Malta, 23Lithuanian University of Health Sciences, Institute for Digestive Research, Kaunas, Lithuania, 24Tampere University Hospital, Department of Gastroenterology and Alimentary Tract Surgery, Tampere, Finland, 25Charles University, IBD Center ISCARE, Prague, Czech Republic, 26AOU Careggi Regional Referral Center for Inflammatory Bowel Disease, Gastroenterology Department, Florence, Italy, 27University of Medicine ‘Victor Babes’, Clinic of Gastroenterology, Timisoara, Romania, 28Complexo Hospitalario Universitario de Vigo, Gastroenterology Department, Vigo, Spain, 29Tartu University Hospital, Division of Endocrinology and Gastroenterology, Tartu, Estonia, 30Soroka Medical Center and Ben Gurion University of the Negev, Department of Gastroenterology and Hepatology, Beer Sheva, Israel, 31Gentofte Hospital, Department of Medical Gastroenterology, Copenhagen, Denmark

DOP020: Thiopurine monotherapy still has a place in the treatment of patients with mild-to-moderate Crohn’s disease in the biological eraECCO '18 Vienna
Year: 2018
Authors:

B. Verstockt1,2*, L. Boets1, G. Van Assche1,2, S. Vermeire1,2, M. Ferrante1,2

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2KU Leuven, Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium

DOP021: Immunosuppressive and anti-TNF treatment is associated with a lower risk of migration from B1-to-B3-stage in Crohn’s disease: 10-year follow-up data from the Swiss IBD cohort studyECCO '18 Vienna
Year: 2018
Authors:

P. Cernoch1, N. Fournier2, M. Scharl1, J. Zeitz3, B. Morell1, T. Greuter1, P. Schreiner1, B. Misselwitz1, E. Safroneeva4, A. Schoepfer5, S.R. Vavricka6, G. Rogler1, L. Biedermann on behalf of the Swiss IBD Cohort Study Group7*

1University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, 2University of Lausanne, IUMSP, Lausanne, Switzerland, 3Klinik Hirslanden, Department of Gastroenterology, Zurich, Switzerland, 4University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland, 5CHUV - Centre Hospitalier Universitaire Vaudois, Department of Gastroenterology, Lausanne, Switzerland, 6Center of Gastroenterology and Hepatology, Zurich, Switzerland, 7University Hospital Zurich, Gastroenterology and Hepatology, Zurich, Switzerland

DOP022: Tacrolimus suppositories as induction therapy for refractory ulcerative proctitis: a randomised controlled trialECCO '18 Vienna
Year: 2018
Authors:

J.E. Kreijne1*, M.R. Lie1, G. Dijkstra2, M. Löwenberg3, G. van Assche4, R.L. West5, D. van Noord5, A.A. van der Meulen - de Jong6, B.E. Hansen1,7, A.C. de Vries1, C.J. van der Woude1

1Erasmus MC, Gastroenterology and Hepatology, Rotterdam, The Netherlands, 2University Medical Center Groningen and University of Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands, 3Academic Medical Center Amsterdam, Gastroenterology and Hepatology, Amsterdam, The Netherlands, 4University Hospitals Leuven, KU Leuven, Gastroenterology, Leuven, Belgium, 5Franciscus Hospital and Vlietland Hospital, Gastroenterology and Hepatology, Rotterdam, The Netherlands, 6Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, The Netherlands, 7Toronto General Hospital, Center for Liver Disease, Toronto, Canada

DOP023: Tofacitinib for the treatment of ulcerative colitis: up to 4.4 years of safety data from global clinical trialsECCO '18 Vienna
Year: 2018
Authors:

W.J. Sandborn1, J. Panés2*, G.R. D’Haens3, B.E. Sands4, C. Su5, M. Moscariello5, T.V. Jones5, R.D. Pedersen5, G.S. Friedman5, N. Lawendy5, G. Chan5

1University of California San Diego, Division of Gastroenterology, La Jolla, CA, USA, 2Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 3Academic Medical Centre, Department of Gastroenterology, Amsterdam, The Netherlands, 4Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, NY, USA, 5Pfizer Inc., Collegeville, PA, USA

DOP024: Tofacitinib achieves symptomatic improvement within 3 days in moderately to severely active ulcerative colitis, regardless of prior tumour necrosis factor inhibitor treatment status: results from OCTAVE induction 1 and 2ECCO '18 Vienna
Year: 2018
Authors:

S. Hanauer1, R. Panaccione2, S. Danese3, A. Cheifetz4, W. Reinisch5*, P.D.R. Higgins6, D.A. Woodworth7, H. Zhang7, G.S. Friedman7, N. Lawendy7, D. Quirk7, C.I. Nduaka7, C. Su7

1Northwestern University, Evanston, IL, USA, 2University of Calgary, Calgary, AB, Canada, 3Humanitas Research Hospital, IBD Center, Department of Gastroenterology, Rozzano, Milan, Italy, 4Beth Israel Deaconess Medical Center and Harvard Medical School, Department of Medicine and Division of Gastroenterology, Boston, MA, USA, 5Medical University of Vienna, Department of Internal Medicine III, Vienna, Austria, 6University of Michigan, Ann Arbor, MI, USA, 7Pfizer Inc., Collegeville, PA, USA

DOP025: Tofacitinib for the treatment of ulcerative colitis: analysis of malignancy rates from the OCTAVE clinical programmeECCO '18 Vienna
Year: 2018
Authors:

G.R. Lichtenstein1, M.A. Ciorba2, G. Rogler3*, D. Quirk4, C.I. Nduaka4, R.D. Pedersen4, N. Lawendy4, G. Chan4, C. Su4, J. Panés5

1Perelman School of Medicine of the University of Pennsylvania, Division of Gastroenterology, Philadelphia, PA, USA, 2Washington University in Saint Louis, Division of Gastroenterology, Saint Louis, MO, USA, 3University of Zürich, Department of Gastroenterology and Hepatology, Zürich, Switzerland, 4Pfizer Inc., Collegeville, PA, USA, 5Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain

DOP026: Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE openECCO '18 Vienna
Year: 2018
Authors:

B.E. Sands1, A.C. Moss2, A. Armuzzi3*, J.K. Marshall4, J.O. Lindsay5, W.J. Sandborn6, S. Danese7, K. Tsilkos8, N. Lawendy9, H. Zhang9, G.S. Friedman9, G. Chan9, D.W. Krichbaum8, C. Su9

1Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, NY, USA, 2Beth Israel Deaconess Medical Centre, Division of Gastroenterology, Boston, MA, USA, 3Presidio Columbus Fondazione Policlinico Gemelli Università Cattolica, IBD Unit, Rome, Italy, 4McMaster University, Division of Gastroenterology, Department of Medicine, Farncombe Family Digestive Health Research Institute, Hamilton, ON, Canada, 5The Royal London Hospital, Barts Health NHS Trust, Department of Gastroenterology, London, UK, 6University of California San Diego, Division of Gastroenterology, La Jolla, CA, USA, 7Humanitas Research Hospital, IBD Center, Department of Gastroenterology, Rozzano, Milan, Italy, 8Pfizer Inc., New York, NY, USA, 9Pfizer Inc., Collegeville, PA, USA

DOP027: Efficacy and safety of an additional 8 weeks of tofacitinib induction therapy: Results of the OCTAVE open study for tofacitinib 8-week induction non-respondersECCO '18 Vienna
Year: 2018
Authors:

B.G. Feagan1, M.C. Dubinsky2, M. Lukas3*, D. Quirk4, C.I. Nduaka4, E. Maller4, N. Lawendy4, C. Kayhan4, W. Wang4, G. Chan4, C. Su4

1Western University, Robarts Clinical Trials, London, ON, Canada, 2Icahn School of Medicine at Mount Sinai Hospital, Department of Pediatrics and Medicine, New York, NY, USA, 3Charles University, Prague, Czech Republic, 4Pfizer Inc., Collegeville, PA, USA

DOP028: Second N-ECCO Consensus Statements on the European nursing roles in caring for patients with Crohn’s disease or ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

K. Kemp1*, L. Dibley2, U. Chauhan3, K. Greveson4, S. Jaghult5, K. Ashton6, S. Buckton7, J. Duncan8, P. Hartmann9, N. Ipenburg10, L. Moortgat11, R. Theeuwen12, M. Verway13, L. Younge14, P. Bager15

1Manchester Royal Infirmary/University of Manchester, Gastroenterology, Manchester, UK, 2University of Greenwich/Barts Heath, School of Nursing/Gastroenterology, London, UK, 3McMasterUniversity, Digestive Diseases, Hamilton, Canada, 4Royal Free Hospital, Gastroenterology, London, UK, 5Karolinska Institutet Danderyd Hospital, Stockholm Gastro Centre, Stockholm, Sweden, 6Hull and East Yorkshire Hospitals, Gastroenterology, Hull, UK, 7Coastal Digestive Health, IBD Clinic, Mountain Creek, Australia, 8St Thomas' Hospital, Gastroenterology, London, UK, 9Gastroenterologische Gemeinschaftspraxis, Gastroenterology, Minden, Germany, 10Ijsselland Hospital, Department of Surgery, ZC Capelle A/D Ijssel, The Netherlands, 11AZ Delta Roeselare-Menen, Gastroenterology, Roeselare, Belgium, 12LUMC, Gastroenterology, Leiden, The Netherlands, 13Leiden University Medical Centre, Gastroenterology, Leiden, The Netherlands, 14Barts and The London NHS Trust, Gastroenterology, London, UK, 15Gastroenterology and Hepatology Aarhus University, Department of Medicine, Aarhus, Denmark

DOP029: Treatment and long-term outcomes of paediatric patients with penetrating Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

L. Kollen1, A. Leroyer2, A. Breton3, M. Fumery4, G. Savoye5, J. Lemale6, D. Morin1, B. Pariente7, E. Mas3, D. Turck8, M. Al Khouri1, P. Blanc9, C. Gower2, G. Pineton de Chambrun9*

1Montpellier University Hospital, Pediatric Gastroenterology and Nutrition, Montpellier, France, 2Lille University Hospital, Epidemiology, Lille, France, 3Toulouse University Hospital, Pediatric Gastroenterology and Nutrition, Toulouse, France, 4Amiens University Hospital, Gastroenterology, Amiens, France, 5Rouen University Hospital, Gastroenterology, Rouen, France, 6Armand Trousseau University Hospital, Pediatric Gastroenterology and Nutrition, Paris, France, 7Lille University Hospital, Gastroenterology, Lille, France, 8Lille University Hospital, Pediatric Gastroenterology and Nutrition, Lille, France, 9Montpellier University Hospital, Gastroenterology, Montpellier, France

DOP030: The efficacy of home telemonitoring vs. conventional follow-up: a randomised controlled trial among teenagers with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

A. Heida1, A. Muller Kobold2, J. Rossen3, A. Kindermann4, F. Kokke5, T. Meij, De6, O. Norbruis7, R. Weersma8, M. Wessels9, T. Hummel10, H. Escher11, H. Wering, van12, D. Hendriks13, L. Mearin14, H. Groen15, H. Verkade1, P. Van Rheenen1*

1University Medical Center Groningen, Paediatric Gastroenterology Hepatology and Nutrition, Groningen, The Netherlands, 2University Medical Center Groningen, Laboratory Medicine, Groningen, The Netherlands, 3University Medical Center Groningen, Microbiology, Groningen, The Netherlands, 4Academic Medical Center, Paediatric Gastroenterology Hepatology and Nutrition, Amsterdam, The Netherlands, 5Wilhemina Kinder Ziekenhuis, Paediatric Gastroenterology Hepatology and Nutrition, Utrecht, The Netherlands, 6VU Medical Center, Paediatric Gastroenterology Hepatology and Nutrition, Amsterdam, The Netherlands, 7Isala Clinic, Paediatrics, Zwolle, The Netherlands, 8University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands, 9Rijnstate Hospital, Paediatrics, Arnhem, The Netherlands, 10Medisch Spectrum Twente, Paediatrics, Enschede, The Netherlands, 11Erasmus Medical Center – Sophia Kinder Ziekenhuis, Paediatric Gastroenterology Hepatology and Nutrition, Rotterdam, The Netherlands, 12Amphia Ziekenhuis, Paediatrics, Breda, The Netherlands, 13Haga Hospital, Paediatrics, The Hague, The Netherlands, 14Leiden University Medical Center, Paediatric Gastroenterology Hepatology and Nutrition, Leiden, The Netherlands, 15University Medical Center Groningen, Epidemiology, Groningen, The Netherlands

DOP031: Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practiceECCO '18 Vienna
Year: 2018
Authors:

D.V. Ankersen*, D. Marker, P. Weimers, J. Burisch, P. Munkholm

North Zealand University Hospital, Frederikssund, Denmark

DOP032: Crohn’s disease patients’ perspectives towards de-escalating immunosuppressive therapy: a comparative French and American surveyECCO '18 Vienna
Year: 2018
Authors:

C.A. Siegel1*, K.D. Thompson2, D. Walls3, J. Gollins4, A. Buisson5, A. Olympie5, L. Beaugerie6, J.-F. Colombel7, E. Louis on behalf of the BIOCYCLE group8

1Dartmouth-Hitchcock Medical Center, Lebanon, USA, 2Dartmouth-Hitchcock Medical Center, Medicine, Lebanon, USA, 3BDJ Solutions, Boston, USA, 4Delta Modelling, Chicago, USA, 5Association François Aupetit, Paris, France, 6Hôpital Saint-Antoine, Paris, France, 7Icahn School of Medicine at Mount Sinai, New York, USA, 8University Hospital CHU of Liège, Liège, Belgium

DOP033: Trends in epidemiology of inflammatory bowel disease among Jewish Israeli adolescents: a population-based studyECCO '18 Vienna
Year: 2018
Authors:

I. Ghersin1*, L.H. Katz2, S. Daher3, R. Shamir4, A. Assa4

1Rambam Health Care Campus, Haifa, Israel, 2Sheba Medical Center, Gastroenterology, Ramat Gan, Israel, 3IDF Medical Corps, Tel Hashomer, Israel, 4Schneider Children's Medical Center, Gastroenterology, Petach Tikva, Israel